Vistin Pharma ASA (OSL:VISTN)

Q3 2025 Vistin Pharma ASA Earnings Call Transcript

Oct 31, 2025 / 07:30 AM GMT

Release Date Price: kr21.8 (-1.36%)

Transcript

Key Points

Positve

Vistin Pharma ASA (FRA:VP4) reported a 3% increase in revenue for Q3 2025 compared to the same quarter last year, driven by a 10% increase in sales volumes.
The company achieved an all-time high production volume of 1,600 metric tons of metformin in the quarter.
Year-to-date EBITDA increased by 16% to 89 million Norwegian kroners, reflecting strong commercial execution.
Vistin Pharma ASA maintains a strong balance sheet with a 74% equity ratio, indicating financial stability.
The company has a long-term renewable energy supply agreement with StarCraft until 2032, ensuring predictable power prices and 100% green renewable hydropower.

Negative

The average sales price (ASP) in Q3 was lower than the previous quarter due to a product mix shift towards more generic volumes.
Global metformin prices have decreased, impacting revenue despite increased sales volumes.
Depreciation costs increased in the quarter, with a one-time effect of 1.3 million Norwegian kroners due to asset replacement.
Net debt stood at 18 million Norwegian kroners as of September, indicating some level of financial leverage.
The company faces potential challenges in maintaining its market share as the global demand for metformin may outpace its production capacity by 2030.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VISTN.OL - Vistin Pharma ASA
Q3 2025 Vistin Pharma ASA Earnings Call
Oct 31, 2025 / 07:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to the visiting Pharma Quarterly Report Q3 2025 conference call. At this time, all participants are in the listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press one and one again. Alternatively, you may submit your questions via the webcast. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Magnus Tolisa, CEO. Please go ahead.

-------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.